Treatment of Parkinson's Disease
US-2022098291-A1 · Mar 31, 2022 · US
Dosing regimes for treatment of synucleinopathies
US12595295B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12595295-B2 |
| Application number | US-202016936457-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 23, 2020 |
| Priority date | Sep 28, 2017 |
| Publication date | Apr 7, 2026 |
| Grant date | Apr 7, 2026 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides dosage regimes for treatment of synucleinopathies. In one regime, a subject receives 3000-5000 mg of an antibody intravenously every 3-5 weeks. In another regime, a subject receives 1300-1700 mg of an antibody intravenously every 3-5 weeks.
First claim
Opening claim text (preview).
What is claimed is: 1 . A method of treating or effecting prophylaxis of a subject having Parkinson's disease, comprising intravenously administering to the subject a dose of 1500 mg of an antibody or an antigen binding fragment thereof against alpha-synuclein at intervals of 3-5 weeks, wherein the antibody comprises a heavy chain variable region comprising SEQ ID NO:10, respectively, and a light chain comprising SEQ ID NO:5. 2 . The method of claim 1 , wherein the antibody comprises a heavy chain comprising SEQ ID NO:37 and a light chain comprising SEQ ID NO:32, wherein the C-terminal lysine of SEQ ID NO:37 may be absent. 3 . The method of claim 1 , wherein the antibody is of human IgG 1 isotype. 4 . The method of claim 1 , wherein the interval is 4 weeks. 5 . The method of claim 1 , wherein the subject receives the antibody every 4 weeks for at least 52 weeks. 6 . The method of claim 5 , wherein the subject has early-stage Parkinson's Disease. 7 . The method of claim 1 , wherein the subject is not receiving symptomatic treatment for Parkinson's disease concomitant with the antibody. 8 . The method of claim 1 , wherein the antibody is administered concomitantly with levodopa. 9 . The method of claim 1 , wherein administering the antibody is preceded by administering a loading dose of 2000 mg of the antibody and optionally uptitration at one or more subsequent dose at greater or equal to 2000 mg but less than 3500 mg until a dose of 3500 mg is reached, all doses being separated by intervals of 3-5 weeks. 10 . The method of claim 1 , further comprising monitoring the subject for a change in movement, cognitive deficit, autonomic dysfunction, gastrointestinal dysfunction, visual hallucination or a psychological symptom. 11 . The method of claim 10 , wherein the monitoring comprises (a) providing a subject with a mobile device programmed to receive and transmit data acquired from sensors internal and/or external to the device relating to movement deficits of a subject having or suspected of having a synucleinopathy, whereafter the subject undergoes a series of movements to reveal movement deficits, if present, and the internal or external sensors of the device acquire data relating to the movements; (b) collecting data transmitted from the mobile device; and (c) comparing the data acquired from the subjects with control data to assess presence or extent of movement deficits in the subject. 12 . The method of claim 11 , wherein the mobile device is programmed to receive and transmit data from at least two external sensors attached to upper and lower limbs of the subject. 13 . The method of claim 11 , wherein the mobile device is carried by the subject and acquires data from an internal sensor.
Assignees
Inventors
Classifications
Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb {(A61B5/1038 takes precedence; motion detection to correct for motion artifacts in physiological signals A61B5/721)} · CPC title
Monitoring or testing the effects of treatment, e.g. of medication · CPC title
comprising antibodies · CPC title
Diagnosing or monitoring movement diseases, e.g. Parkinson, Huntington or Tourette · CPC title
characterised by the dose, timing or administration schedule · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12595295B2 cover?
- The invention provides dosage regimes for treatment of synucleinopathies. In one regime, a subject receives 3000-5000 mg of an antibody intravenously every 3-5 weeks. In another regime, a subject receives 1300-1700 mg of an antibody intravenously every 3-5 weeks.
- Who is the assignee on this patent?
- Prothena Biosciences Ltd, F Hoffmann La Roche Ag, Hoffmann La Roche Inc
- What technology area does this patent fall under?
- Primary CPC classification A61P25/28. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 07 2026 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).